KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Intangibles (2018 - 2025)

Adaptive Biotechnologies' Intangibles history spans 8 years, with the latest figure at $2.2 million for Q3 2025.

  • For Q3 2025, Intangibles fell 44.07% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $2.2 million, down 44.07%, while the annual FY2024 figure was $3.4 million, 33.21% down from the prior year.
  • Intangibles for Q3 2025 was $2.2 million at Adaptive Biotechnologies, down from $2.6 million in the prior quarter.
  • Across five years, Intangibles topped out at $20.3 million in Q3 2021 and bottomed at $2.2 million in Q3 2025.
  • The 5-year median for Intangibles is $5.1 million (2023), against an average of $6.8 million.
  • The largest annual shift saw Intangibles surged 98.78% in 2021 before it plummeted 66.41% in 2022.
  • A 5-year view of Intangibles shows it stood at $20.3 million in 2021, then tumbled by 66.41% to $6.8 million in 2022, then dropped by 24.89% to $5.1 million in 2023, then plummeted by 33.21% to $3.4 million in 2024, then plummeted by 37.08% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Intangibles are $2.2 million (Q3 2025), $2.6 million (Q2 2025), and $3.0 million (Q1 2025).